Sanjay Jayasinghe1, Clayton Chiu1, Helen Quinn1, Rob Menzies2, Robin Gilmour3, Peter McIntyre1. 1. National Centre for Immunisation Research and Surveillance for Vaccine Preventable Diseases, Westmead and Discipline of Child and Adolescent Health, Medical School, University of Sydney, Sydney, Australia. 2. School of Public Health and Community Medicine, University of New South Wales, Sydney, Australia. 3. Communicable Disease Branch, Health Protection NSW, New South Wales Ministry of Health, Sydney, Australia.
Abstract
Background: Unique among high-income countries, Australia has used a 3 + 0 schedule (3 primary doses, no booster) for infant pneumococcal conjugate vaccine (PCV) since January 2005, initially 7 valent (PCV7) then 13 valent (PCV13) from July 2011. We measured vaccine effectiveness (VE) of both PCVs against invasive pneumococcal disease (IPD) using 2 methods. Methods: Cases were IPD notifications to the national surveillance system of children eligible for respective PCVs. For case-control method, up to 10 age-matched controls were derived from the Australian Childhood Immunisation Register. For indirect cohort method, controls were IPD cases due to serotypes not in PCVs. VE was calculated as (1 - odds ratio [OR]) × 100 by logistic regression. VE waning was estimated as odds of vaccine type (VT) IPD in consecutive 12-month periods post-dose 3. Results: Between 2005 and 2014, there were 1209 and 308 IPD cases in PCV7-eligible and PCV13-eligible cohorts, respectively. Both methods gave comparable VE estimates. In infants, VE for 3 doses against VT IPD was 92.9% (95% confidence interval [CI], 27.7% to 99.3%) for PCV7 and 86.5% (95% CI, 11.7% to 97.9%) for PCV13. From 12 months post-dose 3, the odds of VT IPD by 24-36 months increased significantly for PCV7 (5.6, 95% CI, 1.2-25.4) and PCV13 (5.9, 95% CI, 1.0-35.2). Conclusions: For both PCVs in a 3 + 0 schedule, despite similar VE, progressive increase in breakthrough cases only occurred post-PCV13. This supports the importance of a booster dose of PCV13 in the second year of life to maintain protection.
Background: Unique among high-income countries, Australia has used a 3 + 0 schedule (3 primary doses, no booster) for infantpneumococcal conjugate vaccine (PCV) since January 2005, initially 7 valent (PCV7) then 13 valent (PCV13) from July 2011. We measured vaccine effectiveness (VE) of both PCVs against invasive pneumococcal disease (IPD) using 2 methods. Methods: Cases were IPD notifications to the national surveillance system of children eligible for respective PCVs. For case-control method, up to 10 age-matched controls were derived from the Australian Childhood Immunisation Register. For indirect cohort method, controls were IPD cases due to serotypes not in PCVs. VE was calculated as (1 - odds ratio [OR]) × 100 by logistic regression. VE waning was estimated as odds of vaccine type (VT) IPD in consecutive 12-month periods post-dose 3. Results: Between 2005 and 2014, there were 1209 and 308 IPD cases in PCV7-eligible and PCV13-eligible cohorts, respectively. Both methods gave comparable VE estimates. In infants, VE for 3 doses against VT IPD was 92.9% (95% confidence interval [CI], 27.7% to 99.3%) for PCV7 and 86.5% (95% CI, 11.7% to 97.9%) for PCV13. From 12 months post-dose 3, the odds of VT IPD by 24-36 months increased significantly for PCV7 (5.6, 95% CI, 1.2-25.4) and PCV13 (5.9, 95% CI, 1.0-35.2). Conclusions: For both PCVs in a 3 + 0 schedule, despite similar VE, progressive increase in breakthrough cases only occurred post-PCV13. This supports the importance of a booster dose of PCV13 in the second year of life to maintain protection.
Authors: Morgan Congdon; Hwanhee Hong; Rebecca R Young; Coleen K Cunningham; Leslie A Enane; Tonya Arscott-Mills; Francis M Banda; Mamiki Chise; Keneilwe Motlhatlhedi; Kristen Feemster; Sweta M Patel; Sefelani Boiditswe; Tiroyaone Leburu; Samir S Shah; Andrew P Steenhoff; Matthew S Kelly Journal: Clin Infect Dis Date: 2021-07-15 Impact factor: 9.079
Authors: Huiying Chua; Shuo Feng; Joseph A Lewnard; Sheena G Sullivan; Christopher C Blyth; Marc Lipsitch; Benjamin J Cowling Journal: Epidemiology Date: 2020-01 Impact factor: 4.822
Authors: Laura L Hammitt; Anthony O Etyang; Susan C Morpeth; John Ojal; Alex Mutuku; Neema Mturi; Jennifer C Moisi; Ifedayo M Adetifa; Angela Karani; Donald O Akech; Mark Otiende; Tahreni Bwanaali; Jackline Wafula; Christine Mataza; Edward Mumbo; Collins Tabu; Maria Deloria Knoll; Evasius Bauni; Kevin Marsh; Thomas N Williams; Tatu Kamau; Shahnaaz K Sharif; Orin S Levine; J Anthony G Scott Journal: Lancet Date: 2019-04-15 Impact factor: 79.321
Authors: Richael O Mills; Mohammed R Abdullah; Samuel A Akwetey; Dorcas C Sappor; Isaac Cole; Michael Baffuor-Asare; Johan A Bolivar; Gustavo Gámez; Mark P G van der Linden; Sven Hammerschmidt Journal: Microorganisms Date: 2020-12-13
Authors: Maria G Dunn; Fernanda C Lessa; Jacqueline Sánchez; Ramona Cordero; Jesús Feris-Iglesias; Doraliza Cedano; Maria da Glória Carvalho; Josefina Fernández; Kristen A Feemster Journal: J Infect Dis Date: 2021-09-01 Impact factor: 5.226
Authors: Shabir A Madhi; Eleonora Aml Mutsaerts; Alane Izu; Welekazi Boyce; Sutika Bhikha; Benit T Ikulinda; Lisa Jose; Anthonet Koen; Amit J Nana; Andrew Moultrie; Lucy Roalfe; Adam Hunt; David Goldblatt; Clare L Cutland; Jeffrey R Dorfman Journal: Lancet Infect Dis Date: 2020-08-25 Impact factor: 25.071